Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Rigel Pharmaceuticals 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 USA

www.rigel.com P: 650-624-1100 F: 650-624-1101

Description:

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

Key Statistics

Overview:

Market Capitalization, $K 198,208
Enterprise Value, $K 217,788
Shares Outstanding, K 175,405
Annual Sales, $ 116,880 K
Annual Net Income, $ -25,090 K
Last Quarter Sales, $ 35,790 K
Last Quarter Net Income, $ 740 K
EBIT, $ -20,500 K
EBITDA, $ -19,740 K
60-Month Beta 0.95
% of Insider Shareholders 6.43%
% of Institutional Shareholders 66.23%
Float, K 164,126
% Float 93.57%
Short Volume Ratio 0.43

Growth:

1-Year Return -4.20%
3-Year Return -69.62%
5-Year Return -50.87%
5-Year Revenue Growth 162.59%
5-Year Earnings Growth 68.18%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 03/05/24
Latest Earnings Date 05/07/24
Earnings Per Share ttm -0.15
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year -100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-9 on 06/25/03

RIGL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -21.21%
Profit Margin % -21.47%
Debt/Equity -1.83
Price/Sales 1.62
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.16
Interest Coverage -2.65
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar